University of Delaware researchers demonstrate that processing can affect size of nanocarriers for targeted drug delivery.
Significant advances have been made in chemotherapy over the past decade, but targeting drugs to cancer cells while avoiding healthy tissues continues to be a major challenge. Nanotechnology has unlocked new pathways for targeted drug delivery, including the use of nanocarriers, or capsules, that can transport cargoes of small-molecule therapeutics to specific locations in the body.
The catch? These carriers are tiny, and it matters just how tiny they are. Change the size from 10 nanometers to 100 nanometers, and the drugs can end up in the wrong cells or organs and thereby damage healthy tissues.
A common assumption is that once a nanocarrier is created, it maintains its size and shape on the shelf as well as in the body.
However, recent work by a group of researchers led by Thomas H. Epps, III, and Millicent Sullivan in the Department of Chemical and Biomolecular Engineering at the University of Delaware has shown that routine procedures in handling and processing nanocarrier solutions can have a significant influence on the size and shape of these miniscule structures.
Sullivan explains that chemotherapeutic agents are designed to affect processes related to cell division. Therefore, they not only kill cancer cells but also are toxic to other rapidly proliferating cells such as those in hair follicles and bone marrow. Side effects can range from hair loss to compromised immune systems.
“Our goal is to deliver drugs more selectively and specifically to cancer cells,” Sullivan says. “We want to sequester the drug so that we can control when and where it has an impact.”
Although there are a number of routes to creating drug-carrying nanocapsules, there is growing interest in the use of polymers for this application. “Molecular self-assembly of polymers offers the ability to create uniform, tailorable structures of predetermined size and shape,” Epps says. “The problem lies in assuming that once they are produced, they do not change.” It turns out that they do change, and very small changes can have a very large impact.
“At 75 nanometers, a nanocarrier may deliver its cargo directly to a tumor,” Epps says. “But with vigorous shaking, it can grow to 150 nanometers and may accumulate in the liver or the spleen. So simple agitation can completely alter the distribution profile of the nanocarrier-drug complex in the body.”
The work has significant implications for the production, storage, and use of nano-based drug delivery systems.
COMPAMED.de; Source: University of Delaware